NCT01427946 2014-11-13
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
Clinical Trials
3 trialsNCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00431015 2012-12-10
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed